Physician profile
Daniel Webster Ball
NPI 1730175183
$18,650.81
in general payments reported to CMS, 2019-2025
44 companies · $3,236 in 2025
The $3,236 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,221 · 2020: $1,473 · 2021: $2,563 · 2022: $2,810 · 2023: $2,562 · 2024: $2,786 · 2025: $3,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,549 · Education: $34.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,548.81 |
| Education | $34.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,158.80 | 2019-2025 | Mavyret, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,540.98 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,922.11 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,850.62 | 2019-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $1,135.33 | 2019-2025 | |
| Celgene Corporation | $1,042.39 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $649.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $562.46 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $334.47 | 2019-2024 | Dificid |
| Pfizer INC. | $289.56 | 2019-2025 | |
| Celltrion USA INC. | $271.56 | 2024-2025 | Vegzelma, Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $244.01 | 2021-2022 | |
| Genzyme Corporation | $242.31 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $210.82 | 2019-2023 | Clenpiq |
| Ardelyx, INC. | $179.30 | 2022-2025 | Ibsrela |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.